Researchers reported the detection of a mosaic DNMT3A variant in a pair of monozygotic male twins, highlighting the complex clinical implications of post-zygotic genetic changes. The case, published in BMC Medical Genomics, describes how exome sequencing revealed a pathogenic variant in the DNA methyltransferase 3 alpha gene, which plays a critical role in epigenetic modifications. While the twins shared a history of epilepsy, they did not exhibit intellectual or developmental disabilities, a distinction that complicates the interpretation of the genetic finding. The study serves as a case report that underscores the need for further investigation into the long-term health risks associated with such mosaic variants.
The DNMT3A gene is known to encode DNA methyltransferase 3 alpha, an enzyme essential for establishing epigenetic marks in the genome. Pathogenic germline variants in this gene are associated with autosomal dominant Tatton-Brown-Rahman syndrome, a condition characterized by overgrowth, tall stature, unique facial features, intellectual disability, musculoskeletal abnormalities, and seizures. In contrast, pathogenic somatic variants, most commonly the p.Arg882His (p.R882H) variant, are frequently linked to age-related clonal hematopoiesis. This process involves abnormal white blood cell proliferation and is associated with an increased risk for acute myeloid leukemia. The presence of germline variants at amino acid residue 882 in individuals with Tatton-Brown-Rahman syndrome, particularly those who also develop hematologic malignancies, suggests a potential link between these genetic changes and cancer risk.
The clinical significance of post-zygotic mosaic DNMT3A variants remains poorly understood, creating a gap in medical knowledge regarding their contribution to neurological phenotypes and malignancy risk. In this specific case, the twins underwent research-based exome sequencing due to their history of epilepsy. The sequencing analysis identified a pathogenic DNMT3A p.R882H variant in blood-derived DNA from both individuals. The variant allele fractions were measured at approximately 35% in one twin and 34% in the other, indicating that a significant portion of their blood cells carried the genetic change.
To determine the origin of the variant, the research team analyzed DNA from additional tissue sources. The DNMT3A p.R882H variant was absent in DNA samples obtained from buccal swabs of both twins. Furthermore, the variant was not detected in either buccal or blood samples from the twins’ parents. This pattern of presence in blood but absence in buccal tissue and parental samples strongly suggests that the variant is mosaic in nature.
Following a multidisciplinary research team review of the variant-level evidence, the DNMT3A mosaic variant was classified as a reportable pathogenic finding. However, the team emphasized that the clinical relevance of this specific variant remains unclear. The uncertainty stems from the variant’s possible role in the twins’ history of epilepsy and the unknown future risk for hematological malignancy.
The case highlights the challenges of interpreting post-zygotic mosaic variants, particularly the common p.R882H variant, which has well-documented associations with hematologic conditions in somatic contexts. However, the lack of intellectual or developmental disability in these twins contrasts with the typical presentation of germline DNMT3A variants associated with Tatton-Brown-Rahman syndrome. Further studies are needed to establish clear guidelines for reporting such variants and for managing patients longitudinally.
While the DNMT3A p.R882H variant is known to be associated with an increased risk of acute myeloid leukemia in somatic settings, its implications in a mosaic context are less defined.
Subject of Research: Clinical implications of mosaic DNMT3A variants in monozygotic twins
Article Title: Detection of a mosaic DNMT3A variant with potential neurodevelopmental and malignancy risks in monozygotic twins: a case report
Article References: Lea, J. K., Sneddon, T. P., Foss, K., Cardwell, E. B., Dommata, S. S., Ong, R. C., Genetic Determinants of Neurological and Developmental Disorders Study Team, Gucsavas-Calikoglu, M., Peck, S. N., Shiloh-Malawsky, Y., Fan, Z., Heinzen, E. L., Weck, K. E., Powell, B. C., & Hunter, S. E. (2026). Detection of a mosaic DNMT3A variant with potential neurodevelopmental and malignancy risks in monozygotic twins: a case report. BMC Medical Genomics. https://doi.org/10.1186/s12920-026-02461-z
Image Credits: AI Generated
DOI: 10.1186/s12920-026-02461-z
Keywords: DNMT3A, Mosaicism, Genetics, Epilepsy, Hematology, Case Report, Epigenetics, Tatton-Brown-Rahman syndrome, Detection, mosaic, variant, potential
News Source: Ophelia Keating. (November 10, 2026). Mosaic DNMT3A Variant Detected in Monozygotic Twins. Scienmag.



